Introduction {#sec1-1}
============

Sepsis is one of the major causes of mortality and morbidity in hospitalized patients. Blood culture is the gold standard method for the diagnosis of sepsis, and it is included among the early investigation to be sent for sepsis according to the Surviving Sepsis Campaign guidelines.\[[@ref1]\] There is an increase in mortality by about 7.6% with every hour of delay in the initiation of appropriate antimicrobial therapy.\[[@ref2]\] Literature suggests that about 40% of all patients with bacteremia receive inadequate antibiotic treatment until the first notification of a positive blood culture.\[[@ref3]\] Even with advancement in molecular diagnostics, for all practical purposes, blood culture still remains the most important microbiological investigation in the management of sepsis. Rapid turnaround time (TAT) of blood culture reports should be the main motive for a clinical microbiologist for optimal patient care. Collecting recommended volume of blood aseptically for blood culture, sending at least two sets of culture before administering the first dose of antibiotics, utilizing automated blood culture systems over conventional culture, initial reporting of Gram stain report of positive blood culture bottles are few of the measures in reducing TAT of blood culture reports.\[[@ref4][@ref5]\]

As per the standard practice in most of the blood culture laboratory, it takes around 48 h to report antibiotic sensitivity results after a blood culture bottle is flagged positive by automated system.\[[@ref6][@ref7]\] By performing direct susceptibility test from positive blood culture bottles, for example, direct disk diffusion (dDD) test, the TAT to generate antibiotic sensitivity report can reduce to 24 h. However, there is a grave need to address the problems associated with the methodology of performing and reporting dDD.

Since 1980s, there are lot of studies regarding standardization of direct susceptibility testing in various platforms such as disk diffusion, automated, and molecular techniques.\[[@ref8][@ref9][@ref10][@ref11]\] Even with all these studies, there are no standard international documents regarding the dDD testing technique, due to which many clinical laboratories still hesitate to put dDD results on patients chart.\[[@ref7]\] In 2014, Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing (AST) formed an ad-hoc working group to address the standardization of a direct-from-blood culture, and initial phase of study reports good categorical agreement (CA) of dDD with reference disk diffusion (rDD) test.\[[@ref7]\] However, this was a simulated study performed on preserved isolates. More so, the CA between dDD and rDD may vary between laboratories. Therefore, this study was undertaken to determine the CA and understand the various type of errors associated with antibiotic class and pathogen combination, so that caution can be derived while interpreting and reporting dDD results in the earliest meaningful timeframe.

Materials and Methods {#sec1-2}
=====================

The study was conducted in a tertiary care public sector 2200 bedded hospital, South India from August 2017 to January 2018 (6 months). All the positive aerobic blood cultures from patients suspected of having bloodstream infections (BSIs) were subjected to Gram staining. The specimens excluded from study were blood cultures which grew more than one type of isolate and blood culture in which Gram stain smear revealed budding yeast cells. dDD was performed according to CLSI guideline.\[[@ref12]\] Four drops of blood culture broth (from a venting needle) were inoculated onto the Mueller-Hinton agar (MHA) plate, and lawn culture was performed using a sterile swab. After 15--20 min, antibiotic disks as per the direct Grams interpretation were applied on to the MHA surface, using a sterile forceps. Plates are read and interpreted as per CLSI breakpoints, after 18 h incubation.\[[@ref13]\] rDD was performed from the isolate grown on the subculture plates on the next day according to the CLSI guidelines. Zone sizes for quality control strains were evaluated using CLSI quality control ranges published in CLSI M100 ED27-2017.\[[@ref13]\]

Study design and analysis {#sec2-1}
-------------------------

dDD results were compared to the rDD results from the positive blood culture bottles. CA was evaluated, using breakpoints mentioned in CLSI M100 ED27-2017, after excluding any antimicrobials for which the pathogen known to have intrinsic resistance.\[[@ref13]\]

Gram-negative bacilli were tested for panel of 8 antibiotics such as amikacin 30 μg (AK), gentamicin 10 μg (G), ciprofloxacin 5 μg (CF), ceftriaxone 30 μg (CTR), ceftazidime 30 μg (CAZ), cefoperazone sulbactam 75/30 μg (CFS), piperacillin-tazobactam 100/10 μg (PIT), and meropenem 10 μg. All these were included for analysis if the pathogen was identified as a member of *Enterobacteriaceae* family or *Acinetobacter* species. For *Pseudomonas* species, CTR was excluded from the analysis. All other nonfermenters were excluded from the analysis as the antibiotic panel was different from that used in this study.

The antibiotic panel used for Gram-positive cocci in clusters (suspected *Staphylococcus* species) comprised of 6 disks such as penicillin 10 units (PEN), cefoxitin 30 μg (OX), erythromycin 15 μg, co-trimoxazole 1.25/23.75 μg, CF 5 μg, and linezolid 30 μg (LZ) and for Gram-positive cocci in pairs (suspected *Enterococcus* species) ampicillin 10 μg (AMP), high level G 120 μg (HLG), tetracycline 30 μg, and LZ 30 μg.

The performance of dDD as compared to rDD was expressed in terms of CA and categorical disagreement. The categorical disagreement was further characterized into minor error (mE), major error (ME), and very ME (VME) as depicted in [Table 1](#T1){ref-type="table"}. All collected data were entered into Microsoft excel sheet. The analysis of data was carried out using IBM SPSS Statistics for Windows, Version 19.0. (Armonk, NY: IBM Corp).

###### 

Terminologies used for comparison of performance of direct disk diffusion test with reference disk diffusion tests

        CA   Categorical disagreement                             
  ----- ---- -------------------------- --- -------- -------- --- ---
  rDD   S    I                          R   R or S   I        S   R
  dDD   S    I                          R   I        R or S   R   S

R=Resistant, S=Sensitive, I=Intermediate, mE=Minor error, ME=Major error, VME=Very ME, rDD=Reference disk diffusion, dDD=Direct disk diffusion, CA=Categorical agreement

Terminologies used for comparison of performance of dDD test with rDD tests.

Results {#sec1-3}
=======

The workflow in each laboratory is unique and in a routine workup of positive blood culture bottles varies across laboratories and is evolving with new technologies. In laboratories with increased sample load and limited resources, performing dDD and comparing with rDD still remains as the suitable option for abbreviating time to AST report.

As shown in [Figure 1](#F1){ref-type="fig"}, 17, 215 blood cultures were received during the study, of which 71.9% (12,388) cultures were sterile, 12.7% (2194) of cultures were contaminated, 0.2% (27) of the blood cultures were rejected due to inappropriate requisition form or mislabeling of the bottle. The total pathogens were isolated 15.2% (2606); of which the following 57.2% (1491) were excluded from the study: (i) 44.4% (1157) of cultures, the direct bottle grams did not match culture smear, (ii) 6.3% (163) of cultures, dDD did not grow or MHA plate was contaminated, and (iii) 6.6% (171) of the cultures, the dDD was not performed as the bottle smear showed budding yeast cells. The remainder pathogens, 42.8% (1115) were considered for dDD and rDD tests.

![Selection of isolates (pathogens) for performing direct disk diffusion (dDD) test and reference disk diffusion (rDD) test](JLP-11-154-g001){#F1}

[Table 2](#T2){ref-type="table"} shows the distribution of bacteria isolated from the positive blood cultures for which both dDD and rDD tests were performed. *Enterobacteriaceae* accounts for 42.7% (476) of total isolates; nonfermenters 40% (446) and Gram-positive cocci 17.3% (193). Among Gram-negative bacilli, *Escherichia coli* was the most common isolate (18.9%), followed by *Pseudomonas* species (17.3%), *Acinetobacter* species (13.2%), and *Klebsiella* species (13%). Among Gram-positive cocci, *Staphylococcus aureus* was the most common isolate (7.8%) followed by coagulase-negative staphylococci (CoNS, 5%) and *Enterococcus* species (4%). For further analysis of CA between dDD and rDD, we have excluded the isolates which were \<30 (*Proteae* tribe, *Salmonella* species, *Serratia* species, *Pantoea* species, and *Streptococcus* species) as analysis will not be significant and also non-fermenting Gram-negative bacilli other than *Pseudomonas* species and *Acinetobacter* species (other NF-GNB) as they were not further characterized and had an antibiotic panel different from routine Gram-negative antibiotic panel used in this study. Hence, the isolates included for analysis were 965.

###### 

Distribution of bacteria isolated from positive blood cultures for which both direct disk diffusion and test and reference disk diffusion tests were performed

  Organisms                    Number of isolates tested, *n* (%)
  ---------------------------- ------------------------------------
  *Enterobacteriaceae*         476 (42.7)
   *Escherichia coli*          211 (18.9)
   *Klebsiella* species        145 (13)
   *Enterobacter* species      81 (7.3)
   *Proteae* tribe\*           14 (1.3)
   *Salmonella* species\*      12 (1.1)
   *Serratia* species\*        11 (1)
   *Pantoea* species\*         2 (0.2)
  Nonfermenters                446 (40)
   *Pseudomonas* species       193 (17.3)
   *Acinetobacter* species     147 (13.2)
   Other NF-GNB\*\*            106 (9.5)
  Gram-positive cocci          193 (17.3)
   *Staphylococcus aureus*     87 (7.8)
   CoNS                        56 (5)
   *Enterococcus* species      45 (4)
   *Streptococcus* species\*   5 (0.4)
  Total                        1115

Totally 965 isolates were analyzed after excluding the following organisms (i) Isolates\* for which the numbers were\<30; and (ii) Isolates\*\* which were not further characterized and had a different antibiotic panel from routine Gram-negative antibiotic panel used in this study. NF-GNB=Nonfermenting Gram-negative bacilli, CoNS=Coagulase negative *Staphylococcus*

As shown in [Table 3](#T3){ref-type="table"}, overall, dDD performed excellent with a CA of 96% with rDD; mE of 0.9%, ME of 2.1% and VME of 1% fulfilling the performance criteria considered acceptable (ME ≤3%; VME ≤3%) by the international standard organization (ISO 20776-2).\[[@ref7][@ref14]\] VME was highest in *Pseudomonas* species (3%); ME and mE were highest in *Enterobacteriaceae* (2.8% and 1.2%, respectively). When analyzed for the disagreement at number of antibiotics per isolate; it was observed that most of the organisms had a disagreement at ≤2 antibiotics per isolate (10.7%); significant disagreement at ≥2 antibiotics was observed with *Pseudomonas* species (7.3%).

###### 

Performance of direct disk diffusion test compared to reference disk diffusion test for various groups of organisms

  Organisms and antibiotic tested (*n*×Ab=*N*)   CA, *n* (%)   Categorical disagreement, *n* (%)                                                   
  ---------------------------------------------- ------------- ----------------------------------- ----------- ---------- ----------- ------------ -----------
  *Enterobacteriaceae* (437×8 = 3496)            3342 (95.6)   42 (1.2)                            98 (2.8)    14 (0.4)   154 (4.4)   57 (13)      23 (5.3)
  *Pseudomonas* spp. (193×7 = 1351)              1278 (94.6)   13 (1)                              19 (1.4)    41 (3)     73 (5.4)    19 (9.8)     14 (7.3)
  *Acinetobacter* spp. (147×8 = 1176)            1135 (96.5)   11 (0.9)                            17 (1.4)    13 (1.1)   41 (3.5)    17 (11.6)    6 (4.1)
  *Staphylococcus* spp. (143×6 = 858)            845 (98.5)    0                                   12 (1.4)    1 (0.1)    13 (1.5)    7 (4.9)      1 (0.7)
  *Enterococcus* spp. (45×5 = 225)               222 (98.7)    0                                   3 (1.3)     0          3 (1.3)     3 (6.7)      0
  Overall (7106)                                 6822 (96.0)   66 (0.9)                            149 (2.1)   69 (1.0)   284 (4.0)   103 (70.1)   44 (29.9)

*n*=Number of isolates, Ab=Number of antibiotics tested, *N*=Number of isolate-antibiotic combinations. CA=Categorical agreement

The analysis of errors of dDD compared to rDD is vital for carrying out selective reporting of dDD results. We studied this among *Enterobacteriaceae*, *Pseudomonas* species, *Acinetobacter* species, and Gram-positive cocci.

Among *Enterobacteriaceae* \[[Table 4](#T4){ref-type="table"}\], CA was \>95% for all the antibiotics in the panel except for CFS (91.8%) and PIT (92.4%). VME among *Enterobacteriaceae* was well within the acceptable limits (VME ≤ 3%). Higher ME was observed for G (3.2%), CFS (5.5%), and PIT (5.5%).

###### 

Performance of direct disk diffusion test compared to reference disk diffusion test for *Enterobacteriaceae*

  *Enterobacteriaceae* (*n*=437)   CA, *n* (%)   Categorical disagreement, *n* (%)                        
  -------------------------------- ------------- ----------------------------------- ---------- --------- ----------
  AK                               427 (97.7)    0                                   9 (2.1)    1 (0.2)   10 (2.3)
  G                                419 (95.9)    0                                   14 (3.2)   4 (0.9)   18 (4.1)
  CF                               430 (98.4)    2 (0.5)                             4 (0.9)    1 (0.2)   7 (1.6)
  CTR                              426 (97.5)    2 (0.5)                             5 (1.1)    4 (0.9)   11 (2.5)
  CAZ                              419 (95.9)    9 (2.1)                             7 (1.6)    2 (0.5)   18 (4.1)
  CFS                              401 (91.8)    11 (2.5)                            24 (5.5)   1 (0.2)   36 (8.2)
  PIT                              404 (92.4)    9 (2.1)                             24 (5.5)   0         33 (7.6)
  MRP                              416 (95.2)    9 (2.1)                             11 (2.5)   1 (0.2)   21 (4.8)

CA=Categorical agreement, AK=Amikacin, G=Gentamicin, CF=Ciprofloxacin, CTR=Ceftriaxone, CAZ=Ceftazidime, CFS=Cefoperazone sulbactam, PIT=Piperacillin-tazobactam, MRP=Meropenem

[Table 5](#T5){ref-type="table"} depicts that there was a CA of \> 95% in *Pseudomonas* species for all the antibiotics tested except for AK (91.2%), G (92.2%) and CF (91.2%). VME was found to be marginally above the acceptable limits for AK (6.2%), G (5.2%) and CF (4.1%). ME among all antibiotics was within the justifiable limits. mE was high for CF (4.7%), but there are no cutoff limits for interpretation of mEs.

###### 

Performance of direct disk diffusion test compared to reference disk diffusion test for *Pseudomonas* species

  *Pseudomonas* species (*n*=193)   CA, *n* (%)   Categorical disagreement, *n* (%)                        
  --------------------------------- ------------- ----------------------------------- --------- ---------- ----------
  AK                                176 (91.2)    1 (0.5)                             4 (2.1)   12 (6.2)   17 (8.8)
  G                                 178 (92.2)    0                                   5 (2.6)   10 (5.2)   15 (7.8)
  CF                                176 (91.2)    9 (4.7)                             0         8 (4.1)    17 (8.8)
  CAZ                               185 (95.9)    1 (0.5)                             2 (1)     5 (2.6)    8 (4.1)
  CFS                               188 (97.4)    0                                   2 (1)     3 (1.6)    5 (2.6)
  PIT                               187 (96.9)    1 (0.5)                             2 (1)     3 (1.6)    6 (3.1)
  MRP                               188 (97.4)    1 (0.5)                             4 (2.1)   0          5 (2.6)

CA=Categorical agreement, AK=Amikacin, G=Gentamicin, CF=Ciprofloxacin, CAZ=Ceftazidime, CFS=Cefoperazone sulbactam, PIT=Piperacillin-tazobactam, MRP=Meropenem

For *Acinetobacter* species \[[Table 6](#T6){ref-type="table"}\], the CA was \> 95% for all the antibiotics in the panel except for CFS (93.2%). VME and ME among *Acinetobacter* species were well within the acceptable limits; however, the mE was higher for CFS (3.4%).

###### 

Performance of direct disk diffusion test compared to reference disk diffusion test for *Acinetobacter* species

  *Acinetobacter* species (*n*=147)   CA, *n* (%)   Categorical disagreement, *n* (%)                       
  ----------------------------------- ------------- ----------------------------------- --------- --------- ----------
  AK                                  143 (97.3)    1 (0.7)                             0         3 (2)     4 (2.7)
  G                                   140 (95.2)    1 (0.7)                             2 (1.4)   4 (2.7)   7 (4.8)
  CF                                  141 (96)      3 (2)                               2 (1.4)   1 (0.7)   6 (4.1)
  CTR                                 144 (98)      0                                   2 (1.4)   1 (0.7)   3 (2)
  CAZ                                 144 (98)      0                                   1 (0.7)   2 (1.4)   3 (2)
  CFS                                 137 (93.2)    5 (3.4)                             4 (2.7)   1 (0.7)   10 (6.8)
  PIT                                 142 (96.6)    1 (0.7)                             3 (2)     1 (0.7)   5 (3.4)
  MRP                                 144 (98)      0                                   3 (2)     0         3 (2)

CA=Categorical agreement, AK=Amikacin, G=Gentamicin, CF=Ciprofloxacin, CAZ=Ceftazidime, CFS=Cefoperazone sulbactam, PIT=Piperacillin-tazobactam, MRP=Meropenem

Among Gram-positive cocci, both *Staphylococcus* species \[[Table 7](#T7){ref-type="table"}\] and *Enterococcus* species \[[Table 8](#T8){ref-type="table"}\] had CA of \> 95% for all the antibiotics tested. VME was unsatisfactory in *Staphylococcus* species for cefoxitin (4.9%) and for HLG (4.4%) in *Enterococcus* species. ME and mE were satisfactory among both groups.

###### 

Performance of direct disk diffusion test compared to reference disk diffusion test for *Staphylococcus* species

  *Staphylococcus* species (*n*=143)   CA, *n* (%)   Categorical disagreement, *n* (%)                       
  ------------------------------------ ------------- ----------------------------------- --------- --------- ---------
  PEN                                  141 (98.6)    0                                   1 (0.7)   1 (0.7)   2 (1.4)
  OX                                   137 (95.8)    0                                   7 (4.9)   0         7 (4.9)
  CF                                   142 (99.3)    0                                   1 (0.7)   0         1 (0.7)
  ERY                                  140 (97.9)    0                                   3 (2.1)   0         3 (2.1)
  LZ                                   143 (100)     0                                   0         0         0

CA=Categorical agreement, CF=Ciprofloxacin, LZ=Linezolid, PEN=Penicillin, OX=Cefoxitin, ERY=Erythromycin

###### 

Performance of direct disk diffusion test compared to reference disk diffusion test for *Enterococcus* species

  *Enterococcus* species (*n*=45)   CA, *n* (%)   Categorical disagreement, *n* (%)                 
  --------------------------------- ------------- ----------------------------------- --------- --- ---------
  AMP                               44 (97.8)     0                                   1 (2.2)   0   1 (2.2)
  HLG                               43 (95.6)     0                                   2 (4.4)   0   2 (4.4)
  TET                               45 (100)      0                                   0         0   0
  Vancomycin                        45 (100)      0                                   0         0   0
  LZ                                45 (100)      0                                   0         0   0

CA=Categorical agreement, LZ=Linezolid, AMP=Ampicillin, G=Gentamicin, HLG=High level G, TET=Tetracycline

Discussion {#sec1-4}
==========

Rapid identification and antimicrobial susceptibility results of organisms causing BSIs are an absolute priority for the microbiology laboratory. By performing dDD from positive blood cultures, clinicians can get adequate information to tailor the empirical treatment towards targeted antibiotic therapy about 24 h earlier than the conventional rDD test. This in turn can lead to a substantial reduction in mortality and morbidity of the patient.\[[@ref15]\]

CLSI, British Society of Antimicrobial Chemotherapy Guidelines, and European Committee on AST have proposed several methods to perform dDD.\[[@ref6][@ref7][@ref16]\] However, there is a lack of large scale studies and guidelines on reporting of dDD results. Furthermore, the CA and disagreement can have interlaboratory variation based on the methodology followed for performing dDD and the type of automated blood culture bottles used. We designed the present study to determine the potential accuracy of dDD testing.

In the present study, we evaluated 965 pathogens and 7106 organism-antibiotic combinations. Overall, there was a CA of 96% which was extremely satisfactory. The categorical disagreement was found only in 4% of organism-antibiotic combinations; the majority of which were ME (2.1%) followed by VME (1%) and mE (0.9%). Reporting false resistance (in case of ME) will not put the patient into any stake, but may promote drug resistance which can be obviated by verbal communication of rDD results immediately. Percentages of errors (mE, ME, and VME) were overall much lower than the acceptable performance criteria of International Standard ISO 20776-2 (ME ≤3%; VME ≤3%).\[[@ref7][@ref14]\] A study on Gram-negative bacteria conducted by Chandrasekaran *et al*. in the initial results of CLSI study group showed a CA of 87.9% between dDD and rDD; which was lower to that observed in our study. The errors found in this study were VME (0.5%), ME (3.5%), and mE (10%). The present study showed a better performance of dDD with rDD which could be attributed to the large number of diverse clinical isolates tested in our study including Gram-positive organisms. Desai *et al*. reported the overall CA of 90.4% between dDD and rDD with 1.8% VME, 1.9% ME, and 5.8% mE among Gram-negative bacteria.\[[@ref17]\]

Except the two studies quoted above, there is paucity of recent literature comparing dDD with rDD, as most of the studies focused on the comparison of dDD with AST from colonies by automated systems (Vitek, Phoenix, or Micro scan). In a study conducted in an oncology center from Kolkata, Goel *et al*. reported CA of 83.7% between dDD compared with AST from colonies (Gram-negative) by Vitek-2.\[[@ref9]\] In another multicenter study, Coyle *et al*. reported CA of 94.3% for dDD tested with Gram-positive bacteria.\[[@ref18]\] As a novel initiative, we analyzed the categorical disagreement at ≤2 and ≥2 antibiotics. We observed that the categorical disagreement at ≤2 and ≥2 antibiotics were 70.1% and 29.9%, respectively, by which we can derive that even if there is categorical disagreement, majority will have discrepancies with ≤2 antibiotics.

When the performance of dDD with rDD in *Enterobacteriaceae* was evaluated, we found very good results with CA above 90%. CA was least with beta-lactamase inhibitor group (BLI), i.e., with CFS (91.8%) and PIT (92.4%) with ME of 5.5% in both. Similar findings were also observed by Chandrasekaran *et al*.\[[@ref7]\] in a CLSI working group study; reported a CA of 83.3% for PIT and Desai *et al*.\[[@ref17]\] who reported CA of 71.7% for BL-BLI (ampicillin-sulbactam).\[[@ref17]\] Unlike our study, in both these studies, the disagreement was attributed to mE. On assessing the performance of dDD with rDD in *Pseudomonas* species, we observed CA above 90% for all organism-antimicrobial combinations. VME was reported above the acceptable range in AK (6.2%), G (5.2%), and CF (4.1%). In discordance to our results, Goel *et al*. reported a low CA for CAZ (76.1%) and this variation was attributed to VME.\[[@ref9]\] For *Acinetobacter* species CA was extremely satisfactory without any significant errors.

For *Staphylococcus* species, the findings were satisfactory except for cefoxitin (CA 95.8%, ME 4.9%). A similar observation was seen in a study conducted by Bennet *et al*.,\[[@ref19]\] where they reported an agreement of 88% for cefoxitin dDD with rDD. We recommend to report cefoxitin dDD for methicillin-resistant S. aureus (MRSA) and MR-CoNS, however caution should be taken, and clinicians can be communicated if any discrepancies. More so, a supplemental test like MRSA latex can be performed to confirm the result without affecting the TAT. HLG for *Enterococcus* species had an ME of 4.4%. To the best of our knowledge, no other literature was available to compare the results.

The initial results of CLSI study group also showed that variables such as blood culture incubation monitoring systems (BacT/ALERT, BACTEC, and Versa TREK systems) and concentration of bacteria in the broth inoculum are the major discrepancies hindering the performance of dDD. In our study, we did not evaluate these variables, which could be our future venture.\[[@ref7]\]

Conclusion {#sec1-5}
==========

Routine blood culture practice is optimal if bottles are promptly placed on blood culture instrument (within 2 h of collection), punctually removed soon after it flags and the direct Gram stain and antimicrobial susceptibility results communicated rapidly to the clinicians so that they respond expeditiously. dDD is of paramount importance for early institution of targeted therapy and is considered as one of the key stewardship intervention. Our study in concordance to many other studies including the initial report of CLSI working group 2018 give an insight that every laboratory must perform dDD for positively flagged blood culture specimens; the result of which should be confirmed later by performing rDD. We also conclude that one should be vigilant while reporting dDD result of BL-BLI for *Enterobacteriaceae*; aminoglycosides and CF for *Pseudomonas* species; cefoxitin for *Staphylococcus* species and HLG for *Enterococcus* species. Supplementary tests such as MRSA latex should be included when necessary.
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